X4 Pharmaceuticals Inc
(NAS:XFOR)
$
0.371
-0.022 (-5.6%)
Market Cap: 63.27 Mil
Enterprise Value: 10.25 Mil
PE Ratio: 0
PB Ratio: 1.06
GF Score: 30/100 X4 Pharmaceuticals Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) Transcript
Apr 14, 2022 / 02:30PM GMT
Release Date Price:
$1.42
(-4.05%)
Arlinda Lee
Canaccord Genuity LLC - Analyst
Good morning. My name is Arlinda Lee, and I'm a senior biotech analyst at Canaccord Genuity. It's my pleasure to introduce Dr. Paula Ragan, the CEO of X4 Pharmaceuticals. Paula, thanks for joining us today.
Paula Ragan
X4 Pharmaceuticals, Inc. - CEO & President
Thanks so much for having me, Arlinda. Nice to see you.
Questions & Answers
Arlinda Lee
Canaccord Genuity LLC - Analyst
Good to see you, too. So for investors who are new to the X4 story, can you provide an overview of what X4 does? The diseases you intend to treat, and market opportunities in terms of patient size.
Paula Ragan
X4 Pharmaceuticals, Inc. - CEO & President
Yeah. So we are a company focused on diseases that are anchored in dysregulation of the immune system. And I'm sure people can appreciate how broad that might encompass, but we're focused on two key therapeutic areas. There are patients that are born with any deficiencies in the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot